INR 552.6
(3.05%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.07 Billion INR | 26.5% |
2022 | 849.45 Million INR | -16.29% |
2021 | 1.01 Billion INR | 21.28% |
2020 | 836.71 Million INR | -13.1% |
2019 | 962.85 Million INR | 0.78% |
2018 | 955.43 Million INR | -22.13% |
2017 | 1.22 Billion INR | 5.47% |
2016 | 1.16 Billion INR | -13.23% |
2015 | 1.34 Billion INR | -6.76% |
2014 | 1.43 Billion INR | -8.1% |
2013 | 1.56 Billion INR | 7.62% |
2012 | 1.45 Billion INR | 11.76% |
2011 | 1.3 Billion INR | 54.97% |
2010 | 839.4 Million INR | 45.62% |
2009 | 576.43 Million INR | 57.54% |
2008 | 365.88 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -5.92 Billion INR | -651.71% |
2023 Q3 | - INR | -100.0% |
2023 Q1 | - INR | -100.0% |
2023 FY | 1.07 Billion INR | 26.5% |
2023 Q4 | 1.07 Billion INR | 0.0% |
2023 Q2 | 1.17 Billion INR | 0.0% |
2022 Q4 | 849.45 Million INR | 0.0% |
2022 FY | 849.45 Million INR | -16.29% |
2022 Q2 | 1.34 Billion INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2022 Q1 | - INR | -100.0% |
2021 Q4 | 1.01 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 FY | 1.01 Billion INR | 21.28% |
2021 Q2 | 1.12 Billion INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2020 FY | 836.71 Million INR | -13.1% |
2020 Q3 | - INR | -100.0% |
2020 Q4 | 836.71 Million INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2020 Q2 | 985 Million INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 Q1 | - INR | -100.0% |
2019 Q2 | 1.22 Billion INR | 0.0% |
2019 Q4 | 962.85 Million INR | 0.0% |
2019 FY | 962.85 Million INR | 0.78% |
2018 Q3 | - INR | -100.0% |
2018 Q2 | 1.21 Billion INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2018 FY | 955.43 Million INR | -22.13% |
2018 Q4 | 955.43 Million INR | 0.0% |
2017 FY | 1.22 Billion INR | 5.47% |
2017 Q3 | - INR | -100.0% |
2017 Q1 | - INR | -100.0% |
2017 Q4 | 1.22 Billion INR | 0.0% |
2017 Q2 | 1.23 Billion INR | 0.0% |
2016 Q3 | - INR | -100.0% |
2016 FY | 1.16 Billion INR | -13.23% |
2016 Q4 | 1.16 Billion INR | 0.0% |
2016 Q2 | 1.3 Billion INR | 0.0% |
2016 Q1 | - INR | -100.0% |
2015 FY | 1.34 Billion INR | -6.76% |
2015 Q3 | - INR | -100.0% |
2015 Q2 | 1.33 Billion INR | 0.0% |
2015 Q4 | 1.34 Billion INR | 0.0% |
2015 Q1 | - INR | -100.0% |
2014 Q1 | - INR | -100.0% |
2014 Q4 | 1.43 Billion INR | 0.0% |
2014 Q3 | - INR | -100.0% |
2014 FY | 1.43 Billion INR | -8.1% |
2014 Q2 | 1.7 Billion INR | 0.0% |
2013 FY | 1.56 Billion INR | 7.62% |
2013 Q3 | - INR | -100.0% |
2013 Q4 | 1.56 Billion INR | 0.0% |
2013 Q1 | - INR | -100.0% |
2013 Q2 | 1.39 Billion INR | 0.0% |
2012 Q4 | 1.45 Billion INR | 0.0% |
2012 Q2 | 1.3 Billion INR | 0.0% |
2012 Q3 | - INR | -100.0% |
2012 FY | 1.45 Billion INR | 11.76% |
2011 Q4 | 1.3 Billion INR | 0.0% |
2011 FY | 1.3 Billion INR | 54.97% |
2010 FY | 839.4 Million INR | 45.62% |
2009 FY | 576.43 Million INR | 57.54% |
2008 FY | 365.88 Million INR | 0.0% |
2008 Q4 | 365.88 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 93.397% |
Hester Biosciences Limited | 3.59 Billion INR | 70.108% |
Aarti Drugs Limited | 11.5 Billion INR | 90.659% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 86.976% |
Albert David Limited | 1.15 Billion INR | 6.57% |
Alembic Limited | 1.43 Billion INR | 24.967% |
Alkem Laboratories Limited | 48.6 Billion INR | 97.789% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | -64.737% |
Bajaj HealthCare Limited | 4.86 Billion INR | 77.925% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -272.074% |
Brooks Laboratories Limited | 248.6 Million INR | -332.237% |
Eris Lifesciences Limited | 38.26 Billion INR | 97.192% |
FDC Limited | 3.7 Billion INR | 71.03% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 79.259% |
Gufic Biosciences Limited | 5.59 Billion INR | 80.811% |
Hikal Limited | 12.99 Billion INR | 91.731% |
Ind-Swift Limited | 13.45 Billion INR | 92.013% |
Innova Captab Limited | 4.89 Billion INR | 78.07% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 83.022% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -262.092% |
Jubilant Pharmova Limited | 61.27 Billion INR | 98.246% |
Lupin Limited | 96.23 Billion INR | 98.883% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 45.629% |
Medico Remedies Limited | 438.24 Million INR | -145.193% |
Morepen Laboratories Limited | 4.45 Billion INR | 75.906% |
Nectar Lifesciences Limited | 11.21 Billion INR | 90.421% |
Orchid Pharma Limited | 3.84 Billion INR | 72.047% |
Procter & Gamble Health Limited | 2.56 Billion INR | 58.045% |
RPG Life Sciences Limited | 1.38 Billion INR | 22.146% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -66.885% |
Sigachi Industries Limited | 2.53 Billion INR | 57.549% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 92.375% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 47.177% |
Themis Medicare Limited | 1.88 Billion INR | 43.071% |
Unichem Laboratories Limited | 8.06 Billion INR | 86.683% |
Vaishali Pharma Limited | 371.16 Million INR | -189.508% |
Wanbury Limited | 3.15 Billion INR | 65.947% |
Windlas Biotech Limited | 1.76 Billion INR | 39.04% |
ZIM Laboratories Limited | 2.08 Billion INR | 48.358% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 53.066% |
Ipca Laboratories Limited | 33.74 Billion INR | 96.815% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.415% |
Venus Remedies Limited | 1.39 Billion INR | 22.85% |
Sakar Healthcare Limited | 1.26 Billion INR | 14.94% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.294% |
Divi's Laboratories Limited | 18.99 Billion INR | 94.342% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 70.65% |
Mankind Pharma Limited | 23.87 Billion INR | 95.499% |
Sequent Scientific Limited | 8.27 Billion INR | 87.013% |
Laurus Labs Limited | 42.71 Billion INR | 97.484% |
Neuland Laboratories Limited | 5.49 Billion INR | 80.458% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 89.965% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 98.35% |
Zydus Lifesciences Limited | 71.79 Billion INR | 98.503% |
Amrutanjan Health Care Limited | 783.82 Million INR | -37.09% |
Wockhardt Limited | 39.87 Billion INR | 97.305% |
Bal Pharma Limited | 2.51 Billion INR | 57.211% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.995% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 49.046% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -572.469% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 69.348% |
Shilpa Medicare Limited | 12.93 Billion INR | 91.691% |
Valiant Laboratories Limited | 1.05 Billion INR | -1.539% |
Ajanta Pharma Limited | 10.71 Billion INR | 89.967% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 37.606% |
Granules India Limited | 22.95 Billion INR | 95.319% |
Medicamen Biotech Limited | 940.36 Million INR | -14.269% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 7.781% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.808% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.69% |
NATCO Pharma Limited | 10.53 Billion INR | 89.797% |
Suven Life Sciences Limited | 148.62 Million INR | -623.01% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 63.868% |
Strides Pharma Science Limited | 37.68 Billion INR | 97.148% |
Indoco Remedies Limited | 10.34 Billion INR | 89.61% |
Alpa Laboratories Limited | 307.12 Million INR | -249.876% |
Lasa Supergenerics Limited | 541.92 Million INR | -98.283% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 72.397% |